Advertisement
Canada markets open in 4 hours 8 minutes
  • S&P/TSX

    24,162.83
    +194.33 (+0.81%)
     
  • S&P 500

    5,751.07
    +51.13 (+0.90%)
     
  • DOW

    42,352.75
    +341.15 (+0.81%)
     
  • CAD/USD

    0.7355
    -0.0013 (-0.17%)
     
  • CRUDE OIL

    75.89
    +1.51 (+2.03%)
     
  • Bitcoin CAD

    86,009.84
    +1,676.99 (+1.99%)
     
  • XRP CAD

    0.73
    +0.01 (+1.40%)
     
  • GOLD FUTURES

    2,672.10
    +4.30 (+0.16%)
     
  • RUSSELL 2000

    2,212.80
    +32.65 (+1.50%)
     
  • 10-Yr Bond

    3.9810
    +0.1310 (+3.40%)
     
  • NASDAQ futures

    20,070.50
    -156.75 (-0.77%)
     
  • VOLATILITY

    21.31
    +2.10 (+10.93%)
     
  • FTSE

    8,279.45
    -1.18 (-0.01%)
     
  • NIKKEI 225

    39,332.74
    +697.12 (+1.80%)
     
  • CAD/EUR

    0.6705
    -0.0004 (-0.06%)
     

Talphera First Half 2024 Earnings: US$0.31 loss per share (vs US$0.40 loss in 1H 2023)

Talphera (NASDAQ:TLPH) First Half 2024 Results

Key Financial Results

  • Net loss: US$7.78m (loss widened by 78% from 1H 2023).

  • US$0.31 loss per share.

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Talphera Earnings Insights

Looking ahead, revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 9.1% from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for Talphera (1 shouldn't be ignored!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.